Monash IVF Group Limited (ASX:MVF)
Australia · Delayed Price · Currency is AUD | Market Cap | 282.49M +0.7% |
| Revenue (ttm) | 269.46M -0.9% |
| Net Income | 7.43M -70.3% |
| EPS | 0.02 -70.3% |
| Shares Out | 389.63M |
| PE Ratio | 38.16 |
| Forward PE | 15.01 |
| Dividend | 0.03 (3.59%) |
| Ex-Dividend Date | Sep 3, 2026 |
| Volume | 23,076 |
| Open | 0.7100 |
| Previous Close | 0.7100 |
| Day's Range | 0.7100 - 0.7250 |
| 52-Week Range | 0.5750 - 0.8950 |
| Beta | 0.34 |
| Analysts | Buy |
| Price Target | 0.81 (+11.72%) |
| Est. Earnings | Nov 26, 2026 |
About Monash IVF Group
Monash IVF Group Limited engages in the provision of assisted reproductive genetic and specialist women imaging services in Australia and Southeast Asia. It offers diagnostic obstetric, gynecological ultrasound, and fertility treatment services. The company also provides tertiary level prenatal diagnostic, ultrasound, and IVF treatment services. Monash IVF Group Limited was incorporated in 2014 and is headquartered in Cremorne, Australia. [Read more]
Financial Performance
In fiscal year 2026, Monash IVF Group's revenue was 269.46 million, a decrease of -0.90% compared to the previous year's 271.92 million. Earnings were 7.43 million, a decrease of -70.31%.
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for MVF stock is "Buy." The 12-month stock price target is $0.81, which is an increase of 11.72% from the latest price.
News
Monash IVF Group Earnings Call Transcript: H2 2026
FY 2026 saw resilient revenue and improved second-half momentum, with strong international growth offsetting domestic softness. The new Nurture 2030 strategy targets organic volume, market share, and margin gains, while CapEx is set to decline sharply in FY 2027.
Monash IVF Group Annual report: H2 2026
Monash IVF Group has published its H2 2026 annual report on August 30, 2026.
Monash IVF Group Earnings release: H2 2026
Monash IVF Group released its H2 2026 earnings on August 30, 2026, summarizing the period's financial results.
Monash IVF Group Slides: H2 2026
Monash IVF Group has posted slides in relation to its H2 2026 quarterly earnings report, which was published on August 30, 2026.
Monash IVF Group Annual report: H2 2026
Monash IVF Group has published its H2 2026 annual report on August 30, 2026.
Monash IVF Group Earnings release: Trading update
Monash IVF Group released its earnings on June 11, 2026, summarizing the period's financial results.
Monash IVF Group Earnings Call Transcript: H1 2026
Underlying NPAT reached AUD 10.4 million at the upper end of guidance, despite revenue and market share declines in domestic IVF. International and genetics segments showed growth, and margin recovery is targeted through price increases and operational efficiencies into FY 2027.
Monash IVF Group Quarterly report: H1 2026
Monash IVF Group has published its H1 2026 quarterly earnings report on February 25, 2026.
Monash IVF Group Slides: H1 2026
Monash IVF Group has posted slides in relation to its H1 2026 quarterly earnings report, which was published on February 25, 2026.
Monash IVF Group Earnings release: H1 2026
Monash IVF Group released its H1 2026 earnings on February 25, 2026, summarizing the period's financial results.
Monash IVF Group Transcript: AGM 2025
Revenue and EBITDA grew in FY2025 despite sector headwinds and adverse incidents, with no final dividend declared. Board renewal and leadership transition are underway, and strategic investments continue, while competitive pressures and risk management remain key focus areas.
Monash IVF Group Slides: FY 2025
Monash IVF Group has posted slides in relation to its FY 2025 quarterly earnings report, which was published on November 19, 2025.